T he enactment of the massive health reform legislation earlier this year will bring with it significant changes for specialists and their practices-in dermatology and elsewhere. This article (1) reviews the "nuts and bolts" changes to federal payment and enforcement rules and (2) examines the innovative concepts of care and related mechanisms that the new law is intended to institute or advance, leading to new accountability for providers.
pAYment AdJustments And reLAted chAnges
The new law, titled the patient protection and affordable Care act (ppaCa), may have its most significant effect on medicare payments to dermatologists and other physicians through the implementation of a relative value unit (rVu) "modifier" system to vary payments based on the quality of care compared with the cost. The payment modifier will be adjusted for risk and geographically standardized. its use is relatively far in the future, however. The secretary of the u.s. Department of Health and Human services (HHs) must publish the specific cost and quality measures by 2012 and begin to put the payment modifier into effect through the 2013 physician fee schedule rulemaking process. The payment modifier will not be applied until 2015 for specific groups of physicians as the secretary deems appropriate and in 2017 for all physicians.
The secretary must also develop and update providerlevel outcome measures for both physicians and for hospitals. The measures may include outcome measurement for acute and chronic diseases and for primary and preventive care, including measurements for distinct patient populations.
an existing program to link payment to quality, the physician Quality reporting initiative (pQri), will continue through 2014. The bonus level is set at 1% in 2011 and 0.5% in 2012 through 2014. starting in 2014, eligible professionals who do not satisfactorily submit quality information will be penalized, leading to reduced rates in 2015 and later. The penalty will be equal to 1.5% of payment in 2015, increasing to 2% in 2016 and thereafter. Hss is now required to provide timely feedback to physicians on their performance in submitting data on quality measures and to establish an informal process to contest a determination that the physician did not satisfactorily submit quality measures information. The secretary must also integrate the pQri with the standards for meaningful use of certified electronic health records under the 2009 american recovery and reinvestment act, issuing a plan by 2012.
in another payment reform, rVus for medicare physician fee schedule services will be adjusted periodically to attempt to correct any services that might not be correctly valued. HHs must examine the codes and families of codes that have experienced the fastest growth or substantial changes in practice expense, codes that represent new technologies or services, multiple codes that are often billed in connection with a single service, codes associated EditOri A L Disclosures James A. Barker Jr. is a partner with the health care practice group Drinker, Biddle & Reath LLP, in Washington, D.C. Neil S. Olderman is a partner and chairman of the firm and is based in Chicago. The authors represent clients with an interest in the health care industry. They have no other conflicts of interest to disclose. with low relative value, and codes that have not been reviewed since implementation of the resourcebased relative value scale.
increased public information about physician behavior is another initiative under the new law. The ppaCa requires that by september 2013 the secretary make publicly available, on the internet in a searchable format, information disclosing payments (or other transfers of value) by pharmaceutical manufacturers to physicians greater than $10 (unless more than $100 is paid in a year) and describing physician ownership or investment interests in those manufacturers and in group purchasing organizations. The ownership or investment interests to be reported and published will not include any publicly traded securities or mutual funds, however. manufacturers and drug distributors will also be required to report information describing the distribution of drug samples to practitioners, although publication is not yet mandated.
for rural practitioners, the new law extends a floor on the Geographic practice Costs index (GpCi) to the work portion of the medicare physician fee schedule through 2010. This increases practitioner fees in certain rural areas. ppaCa also requires that the employee wage and rent portions of the GpCi reflect three quarters of the difference between the relative costs of such items in each of the different fee schedule areas and the national averages in 2010 and one half of that difference in 2011. The secretary must, by 2012, make any adjustments needed to ensure accurate geographic adjustments across fee schedule areas.
a new emphasis on primary care and preventive services is a recurring theme in the ppaCa. for example, the ppaCa increases medicaid payment rates for primary care physician services to medicare levels in 2013 and 2014. other incentives to attempt to increase the primary care workforce include a 10% medicare bonus payment for certain evaluation and management codes starting in 2011 and a provision for medicare coverage of annual wellness visits and a personalized prevention plan, with no co-payment or deductible.
Various new initiatives to improve enforcement of anti-kickback laws have been legislated. perhaps most noteworthy is a new provision that requires providers to report and return overpayments within 60 days of identifying them. This provision was effective immediately on enactment of the law. The meaning of identification is not stated, but the rule puts a new burden on providers to act quickly after becoming aware of an overpayment.
neW AccountAbiLitY: pAYment And cAre deLiverY innovAtions And initiAtives
The ppaCa promotes a new paradigm intended to help shift reimbursement based on the type and volume of work done to a system that rewards providers for delivering both savings and good clinical results. The broad outline of the new reimbursement model is set out in the ppaCa, but details will slowly emerge from new regulations. The details will be essential to identify the best strategies for adapting to the alternative care delivery models, where appropriate.
We do know that the ppaCa's payment transformation initiatives attempt to ensure quality and efficiency through accountability for a defined population, as well as patient-centered care and management through primary care providers and the use of emerging infrastructure (including electronic records, disease registries, electronic reporting, and "telehealth" capabilities). These are hallmarks of provider collaboration, risk sharing, and cost sharing.
for those who treat complex, multidisciplinary disease states, like psoriasis, the ppaCa's initiatives mean that providers will need to be able to work collaboratively with others in the continuum of care to manage the care and cost to certain targets, to use quality and outcomes data to refine treatment protocols and patterns, and to use electronic data systems to report quality and evaluate care patterns and results (and to defend the economics of at least some care patterns using evidencebased medicine). providers who participate in one or more of the proposed new payment models will have to justify high-cost care patterns (including, potentially, the prescribing of certain biologics) as the most cost-efficient quality care for the patientspecific indication. factors such as prevention of related complications and inpatient admissions, and the adverse effect on treatments for unrelated conditions, are sure to be considered.
Center for Medicare and Medicaid Innovation
a new federal entity, the Center for medicare and medicaid innovation (Cmi), is charged with promoting payment and care delivery models that "improve the coordination, quality, and efficiency of health care services." Cmi will essentially be the "nerve center" for the development of medicare demonstration projects.
The payment and delivery models are not intended to be separate. The models may, in fact, complement each other and may be deployed simultaneously for one population. The law touts accountable Care organizations (aCos) as an effective model to manage costs and improve quality. The new act did not clear away the significant legal hurdles that must be overcome for these models to be deployed, including potential issues under the federal physician self-referral prohibitions (stark law), anti-kickback statute, Civil monetary penalty law, and restrictions on tax-exempt organizations, as well as state laws on physician fee-splitting, corporate practice of medicine and insurance laws on "any willing provider," and the assumption of insurance risk. of the models emphasized by the ppaCa, aCos and medical Homes have garnered the most attention. a medical Home model (essentially an informal network of providers for a particular patient) may be embedded within an aCo. aCos, unlike fee-for-service models, tie payment to quality, outcomes, and resource utilization, not volume of care. aCos are multiprovider (hospitals, physicians, ancillary providers, and other medicare suppliers) arrangements that are integrated economically and in other ways (shared governance, formal legal structure) to manage the care of a patient population of 5,000 or more medicare beneficiaries assigned by primary care physician participant. The aCo is charged with managing and coordinating care reimbursed under medicare parts a and B and with receiving and distributing shared savings to provider-participants. aCos are the more advanced, economically integrated, and electronically enabled "cousins" of physician-hospital organizations.
Accountable Care Organizations and Shared Savings
The secretary will establish an aCo shared savings program no later than January 1, 2012. Notably, participating providers will still be paid on a fee-forservice basis under medicare, but they will also be able to earn a percentage of the savings if the cost of care for an aCo's patients falls below the estimated average per beneficiary medicare expenditure for parts a and B services as estimated by the secretary.
To determine the baseline for evaluating savings, the secretary will use the three most recent years of available medicare fee-for-service costs and adjust the baseline for beneficiary characteristics and other relevant factors. assuming certain quality performance metrics are met for an aCo's beneficiary population, the aCo will be eligible to share the savings against the baseline in an amount determined by the secretary (medicare will get the other share). The aCo would then divide its side of the savings among provider participants. improving results by avoiding the assignment of high-cost patients (among others) to an aCo will be prohibited. many hospitals and health systems are likely to deploy aCos to survive under health reform. Dermatologists will have opportunities to evaluate whether they should be part of an aCo and, if so, which one. To evaluate the options, physicians will need to keep abreast of what the secretary ultimately articulates as a viable and effective aCo.
Medical Homes
medical Homes are defined in the ppaCa as "a mode of care that includes: personal physicians; a whole person orientation; coordinated and integrated care; safe and high quality care through evidence informed medicine, appropriate use of health information technology, and continuous quality improvements; expanded access to care; and payment that recognizes added value from additional components of patient-centered care." medical Homes are not separate entities but are cooperative arrangements of providers for patient treatment. The new law provides grant support and additional compensation (10% bonus) for primary care providers (defined as family, geriatric, internal, and pediatric physicians and nurse practitioners; clinical nurse specialists; and physician assistants for whom 60% of allowed charges were for primary care services). it is likely that psoriasis patients will be managed and their care coordinated through medical Homes in the future. Dermatologists will need to be familiar with care coordination strategies affecting psoriasis patients and the most recent data on success rates of competing treatments.
Bundled Payments for Inpatient Episodes of Care
a 3-year pilot program designed to bundle the payments for inpatient episodes of care for eight medical conditions will begin no later than 2013. like the aCo model, payment will be predicated on achievement of improved quality. The model, to be set by the secretary, will provide payment for all applicable services and certain care coordination, medication reconciliation, and transitional care and other services the secretary deems appropriate to include. in the end, the payment amount will be less than what would otherwise have been paid under medicare for the condition and episode of care.
Electronic medical records will play a key role in tracking and reporting quality measures and other indicators of cost and quality. an episode of care for included conditions will include the 3 days before admission, the course of the admission, and the 30-day period that follows discharge. The secretary will determine the services to be included under the bundled payment, but the payment will certainly include acute care as well as inpatient and outpatient physician services. Whether the eight medical conditions selected for the pilot program will include or relate to those treated by dermatologists will merit watching.
concLusion
Dermatologists treating complex disease states like psoriasis will be evaluated on quality outcomes and evidenced-based medicine whether or not they are part of an alternative care model. medicare and other payors will review costly episodes of care and impose accountability for outcomes. mandated cost savings will accompany this trend.
Dermatologists need to be aware of the progress in developing the new models for care delivery, payment, and improved quality and how their practices and incomes might be impacted. There may be no reason for a dermatologist to be involved in a particular aCo or payment pilot. While the models are in development, however, staying informed and being involved with professional associations and advocacy groups are undoubtedly the prudent course.
